Implementing High Dose Oral Methylprednisolone for a Multiple Sclerosis Relapse in the Outpatient Setting

Main Article Content

Lauren Schleicher, PharmD, BCACP Lisa Hawk, PharmD, BCPP Kate Hartkopf, PharmD, BCACP Christopher Hulstein, PharmD, CSP Natasha Frost, MD, MS FAAN

Abstract

Background


Intravenous methylprednisolone is the standard of care for a multiple sclerosis relapse. However, intravenous medications can create several barriers for patients and healthcare organizations. A non-inferiority study by Le Page et al. demonstrated no difference between a patient’s multiple sclerosis disability score when treated with high dose oral versus intravenous methylprednisolone. Implementing an oral methylprednisolone workflow for a multiple sclerosis relapse leads to healthcare cost savings and decreased healthcare utilization.


 


Methods


A neurology clinical pharmacist partnered with neurology providers to create and implement a standardized workflow for high dose oral methylprednisolone to treat multiple sclerosis relapses. From October 2018 – April 2022, patients were included in the retrospective analysis if they were prescribed oral methylprednisolone for a 3 or 5 day treatment course for the purpose of an multiple sclerosis relapse by a neurology provider from the same multiple sclerosis clinic. The primary outcome was evaluating healthcare utilization measured by infusion center chair time saved and direct health system cost savings.


 


Results:


Overall, 290 three-day oral methylprednisolone treatment courses and 50 five-day treatment courses were prescribed. This saved the infusion center 1,680 hours of medication administration time and contributed to an estimated $80,875 in health system cost savings.


 


Conclusion and Relevance:


Implementing a high dose oral methylprednisolone workflow for a multiple sclerosis relapse at an outpatient neurology clinic did help reduce health system cost and infusion center chair time.

Keywords: High Dose Oral Methylprednisolone, Multiple Sclerosis Relapse, Methylprednisolone, Multiple Sclerosis Relapse in the Outpatient Setting

Article Details

How to Cite
SCHLEICHER, Lauren et al. Implementing High Dose Oral Methylprednisolone for a Multiple Sclerosis Relapse in the Outpatient Setting. Medical Research Archives, [S.l.], v. 12, n. 3, mar. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5195>. Date accessed: 13 apr. 2024. doi: https://doi.org/10.18103/mra.v12i3.5195.
Section
Research Articles

References

1. Managing Relapses. National Multiple Sclerosis Society, https://www.nationalmssociety.org/Treating-MS/Managing-Relapses

2. Finkelsztejn A. Multiple sclerosis: Overview of disease-modifying agents. Perspectives in Medicinal Chemistry. 2014;6. doi:10.4137/pmc.s13213

3. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010; 133(7):1900-1913. doi:10.1093/brain/awq076

4. Durelli L, Cocito D, Riccio A, et al. High‐dose intravenous methylprednisolone in the treatment of multiple sclerosis. Neurology. 1986;36(2):238-238. doi:10.1212/wnl.36.2.238

5. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. Journal of Neurology, Neurosurgery & Psychiatry. 1987;50(5):511-516. doi:10.1136/jnnp.50.5.511

6. Barnes D, Hughes R, Morris R, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. The Lancet. 1997; 349(9056):902-906. doi:10.1016/s0140-6736(96)06453-7

7. Levit L, Byatt L, Lyss A, et al. Closing the Rural Cancer Care Gap: Three Institutional Approaches. JCO Oncology Practice. 2020; 16(7):422-430 https://ascopubs.org/doi/full/10.1200/OP.20.00174

8. Le Page E, Veillard D, Laplaud D, et al. Oral versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP): A Randomized, Controlled, Double-Blind, Non-Inferiority Trial. The Lancet. 2015;386(9997): 974-981 https://doi.org/10.1016/s0140-6736(15)61137-0

9. “National Infusion Center Association's COVID-19 Guidance and Resources.” National Infusion Center Association, 28 Apr. 2021, https://infusioncenter.org/infusion_resources/covid-19/

10. Farez M, Correale J, Armstrong M, et al. Practice Guideline Update Summary: Vaccine-Preventable Infections and Immunization in Multiple Sclerosis. Neurology. 2019;93(13): 584-594 https://doi.org/10.1212/wnl.0000000000008157

11. Sicotte, Nancy, Banwell B, Cross A, et al. Timing MS Medications with Covid-19 Vaccines. National Multiple Sclerosis Society. Accessed November 19, 2021. https://www.nationalmssociety.org/coronavirus-covid-19-information/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines

12. May A, Morgan O, Quairoli K. Incorporation and Impact of a Clinical Pharmacist in a Hospital-Based Neurology Clinic Treating Patients with Multiple Sclerosis. International Journal of MS Care. 2020;23(1):16-20 https://doi.org/10.7224/1537-2073.2019-032